Ibrutinib

Facts of IBRUTINIB

  • Brand Name- Ibrunat
  • Innovator Brand Name- Imbruvica
  • API: Ibrutinib
  • Strength: 140 mg
  • Supplied as: 90 capsules or 120 capsules pack.
Get Price

Description

What is Ibrutinib and what it is used for:

Ibrutinib is a thalidomide analogue drug. Ibrutinib is recommended for the treatment of patients with:
  • Mantle cell lymphoma who have received at least one therapy earlier.
  • Chronic lymphocytic leukemia/Small lymphocytic lymphoma.
  • Small lymphocytic lymphoma(SML) or Chronic lymphocytic leukemia (CML) with 17p deletion.
  • Waldenström’s macroglobulinemia (WM)
  • Marginal zone lymphoma patients who need systemic therapy and have received at least one anti-CD20-based therapy earlier.
  • Chronic graft-versus-host disease (cGVHD) after the failure of one or more lines of systemic therapy.

Source: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205552s026,210563s002lbl.pdf

Recommended Dosage

Ibrutinib should be taken orally at about the same time each day with a glass of water. Do not cut, crush or chew. Ibrutinib capsules must be gulped whole with water. One should avoid opened, broken, or chewed capsules.

  • In Mantle Cell Lymphoma and Marginal Zone Lymphoma patients: The dose of Ibrutinib recommended by healthcare professionals for Mantle Cell Lymphoma and Marginal Zone Lymphoma is 560 mg orally once daily until disease progression or unacceptable toxicity.
  • In Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenström’s Macroglobulinemia patients: The recommended dose of Ibrunat for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenström’s Macroglobulinemia is 420 mg orally once daily until disease progression or unacceptable toxicity. The recommended dose of Ibrunat for CLL/SLL when used in combination with bendamustine and rituximab (administered every 28 days for up to 6 cycles) is 420 mg orally once daily until disease progression or unacceptable toxicity.
  • In Chronic Graft versus Host Disease patients: The recommended dose of Ibrunat for Chronic Graft versus Host Disease is 420 mg orally once every day until cGVHD progression, recurrence of an underlying malignancy, or unacceptable toxicity. When a patient no longer needs the therapy for the treatment of cGVHD, Ibrunat should be discontinued, considering the medical assessment of the individual patient.

Ibrutinib side effects:

The most common adverse reactions include diarrhea, thrombocytopenia, neutropenia, fatigue, anemia, musculoskeletal pain, bruising, upper respiratory tract infection, rash, and nausea.

More Info.

Warning & Precautions

  • Before taking Ibrutinib, inform your doctor if you have had recent surgery or plan to have surgery. Your healthcare provider may interrupt this drug for any planned medical, surgical, or dental procedure.

  • Before initiating treatment with this medication, talk to your doctor if you have bleeding problems.

  • If you have a heart rhythm problem, smoke, or have a medical condition that increases your risk of heart diseases, like high blood pressure, high cholesterol, or diabetes, please interact with your doctor.

  • Do not administer Ibrutinib capsules if you have an infection or have liver-related problems.

  • Avoid the intake of Ibrutinib 140 mg if you are pregnant or planning to become pregnant. Ibrutinib may harm the fetus.

  • Patients must be advised about all the common side effects associated with the Ibrutinib 140 mg.

  • Patients should be instructed to inform their doctor about all the concomitant drugs, including prescription medicines, over-the-counter medications, vitamins, and herbal products.

  • Patients must be instructed that they might have diarrhea or loose stools and must contact their healthcare provider if their diarrhea persists.

  • Healthcare providers should advise patients to maintain appropriate hydration while on ibrutinib tablets.

  • Healthcare professionals should counsel patients to report any possible signs of lightheadedness, dizziness, shortness of breath, fainting, chest discomfort, and palpitations.

Drug Approved to Prevent Lung Cancer


  • Alimta (pemetrexed 500 mg inj)

  • IBRUTINIB- (ibrunat 140mg)

  • Noxalk (Ceritinib)

  • Crizalk (crizotinib 250 mg)

  • ERLONAT (Erlotinib)

  • GEFTINAT (Gefitinib 250 mg)

  • ZYKADIA® (ceritinib 150 mg)

  • Opdivo (nivolumab)

  • CYENDIV (Nintedanib)

  • Mitosol (Mitomycin)

Commonly Asked Questions

WHAT IS THE PRICE OF IBRUTINIB?

Ibrutinib 140 mg price is affordable. You can purchase the drug from any legitimate pharmaceutical company. Contact +91 8130290915 for IBRUTINIB price.

IS IBRUNAT A GENETIC DRUG?


Yes, Ibrunat 140 mg is a generic version of Imbruvica, containing Ibrutinib as the Active Pharmaceutical Ingredient (API).


Where is the medicine Ibrutinib available?

IBRUTINIB 140 mg can be made available in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Jaipur, Lucknow, Cochin, and Punand other cities in India.

The Indian Pharma can facilitate the supply of IBRUTINIB (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

How will the order be confirmed?


The order will be confirmed only after the receipt of

  • Valid prescription of Clinician

  • Import permit if applicable

Send your inquiry to find Ibrutinib in UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela, Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia, Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand. China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong